Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Rev. chil. infectol ; 33(3): 268-274, jun. 2016. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-791018

RESUMO

El síndrome de intestino irritable (SII) es un trastorno funcional digestivo de etiología multifactorial. En su fisiopatología se describen diversos factores, tanto biológicos, como psicológicos y ambientales, que afectan el estado de activación de células inmunes en la mucosa intestinal. Entre los factores ambientales se incluye la presencia de alguna parasitosis intestinal. El síndrome de intestino irritable post-infeccioso (SII-PI) es reconocido como un subgrupo de estos trastornos, cuya aparición de los síntomas es posterior a una infección intestinal provocada por agentes microbianos. A pesar de que en Chile hay pocos estudios respecto a la relación entre SII y parasitosis intestinal, se ha descrito la existencia de una asociación positiva entre SII e infecciones por Blastocistis hominis, uno de los parásitos prevalentes en Chile. En otros países, se ha descrito además una relación entre SII, amebiasis y giardiasis. Por la alta prevalencia de parasitosis en nuestro país, existe la necesidad de ampliar los estudios para clarificar la fuerza de la asociación entre parasitosis y SII.


Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract characterised by multi-factorial aetiology. In IBS physiopathology are involved diverse factors between them biological, psychosocial, and environmental components which affect the immune activation status of gut mucosa. Among these factors is recognized the intestinal parasitosis. Post-infection IBS (PI-IBS) is recognised as a subgroup of functional disorders whose symptoms onset appear after a symptomatic intestinal infection caused by microbial agents. There are few studies regarding of relationship between IBS and intestinal parasitosis in Chile. However, is has been well described a positive association between IBS and Blastocystis hominis infections, one of prevalent parasites in Chile. In other countries, is also described a relationship between IBS and amebiasis and giardiasis. Both, characterized by a common mode of transmission through water as well as contaminated food. Because the high prevalence of parasitosis in our country it is necessary to expand the association studies to clarify the strength of the parasites ethiology in IBS.


Assuntos
Humanos , Síndrome do Intestino Irritável/parasitologia , Enteropatias Parasitárias/complicações , Chile , Giardíase/complicações , Giardia lamblia/patogenicidade , Infecções por Blastocystis/complicações , Blastocystis hominis/patogenicidade , Síndrome do Intestino Irritável/fisiopatologia , Entamoeba histolytica/patogenicidade , Entamebíase/complicações , Enteropatias Parasitárias/fisiopatologia , Mucosa Intestinal/parasitologia
2.
Rev. Hosp. Clin. Univ. Chile ; 26(1): 24-32, 2015. tab, graf
Artigo em Espanhol | LILACS | ID: lil-788846

RESUMO

Irritable Bowel Syndrome (IBS) is a functional disorder characterized by abdominal discomfort associated with changes in bowel habit and increased intestinal sensitivity. It is one of the most common disorders of digestive health in Chile as well as in the world. Although the pathophysiological mechanisms of IBS have yet to be fully established, it is known that (epi-) genetic factors are involved in the development of the disorder. Bcl3 (B-cell leukemia/lymphoma 3) is a regulatory protein of the intestinal inflammatory response, specifically, with regard to the signaling pathways of NF-kB (Nuclear Factor-kB). Among the variability of the human genome, the gene encoding Bcl3 contains the polymorphism SNPs rs2927488 (variants A/G) which has been associated with susceptibility to developing Inflammatory Bowel Disease (IBD). Furthermore, the presence of this polymorphic variant has been correlated with increased levels of Bcl3 gene expression in patients with Crohn’s Disease. Our laboratory is focused on understanding the potential relationship between Bcl3 and IBS. Our preliminary studies describe an increased expression of Bcl3 at the intestinal mucosal epithelium in IBS patients with a diarrheal-phenotype (IBS-D). We are now interested to investigate if the presence of the variant SNP rs2927488(A/G) is a susceptibility factor for IBS development and to understand the significance of its relationship with Bcl3 expression, in Chilean IBS patients. In this review, we focus primarily on the relationship between rs2927488(A/G) polymorphism of Bcl3 gene, its protein expression and its mechanisms of control over the inflammatory response...


Assuntos
Humanos , Polimorfismo Genético , Síndrome do Intestino Irritável/epidemiologia , Síndrome do Intestino Irritável/fisiopatologia , Síndrome do Intestino Irritável/genética
3.
Rev. méd. Chile ; 135(10): 1245-1252, oct. 2007. graf, tab
Artigo em Espanhol | LILACS | ID: lil-470704

RESUMO

Background: Recent studies have described a high percentage of small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS). However, the prevalence of SIBO has not been well established in other functional disorders. Aim: To evaluate the prevalence of SIBO in patients with different functional gastrointestinal disorders (FGID). Material and methods: Patients with FGID completed a self-administered questionnaire providing information to diagnose functional disorders on the basis of Rome II criteria. SIBO was assessed using a standardized lactulose breath test. A basal value of breath hydrogen (H2) >20 ppm and/or two lectures of HZ values >20 ppm during the first 60 minutes were considered suggestive of SIBO. Results: We studied 367 patients with a mean age of 50 years (87 percent females). Of these, 225 had IBS (45 constipation predominant, 121 diarrhea predominant and 59 alternating type), 33 had functional constipation, 83 had functional bloating and 26 had functional diarrhea. SIBO was found in 76 percent of patients with IBS, 73 percent of those with functional constipation, 69 percent of those with functional diarrhea and 68 percent of those with functional bloating. Conclusions: This study confirms a high percentage of SIBO in patients with IBS and other FGID. The eradication of SIBO should be considered as a therapeutic tool in these patients.


Assuntos
Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Bactérias/crescimento & desenvolvimento , Constipação Intestinal/microbiologia , Diarreia/microbiologia , Flatulência/microbiologia , Síndrome do Intestino Irritável/microbiologia , Testes Respiratórios/métodos , Intestino Delgado/microbiologia , Prevalência , Estudos Prospectivos , Inquéritos e Questionários
4.
Rev. méd. Chile ; 135(3): 287-293, mar. 2007. tab
Artigo em Espanhol | LILACS | ID: lil-456613

RESUMO

Background: Helicobacter pylori is a pathogenic bacterium that infects a significant number of individuals. At present, therapeutic strategies to eradicate this bacterium depend on our knowledge of its resistance to antimicrobials. Aims: To evaluate the primary resistance of H pylori to metronidazole (Mtz), clarithromycin (Cla), and tetracycline (Tet) in symptomatic out-patients. Material and Methods: Fifty independent isolates of H pylori were obtained by endoscopy-assisted gastric biopsy from patients attending the University of Chile Clinical Hospital, that previously had not been treated with an eradication regime against this bacterium. The minimal inhibitory concentration of each antimicrobial was determined by agar dilution method. Results: Forty five and 27 percent of the isolates were found to be resistant to Mtz and Tet, respectively; the majority of these resistant isolates were from patients older than 21 years. Twenty percent of isolates were resistant to Cla; these were distributed evenly among different ages. Thirty two percent of the isolates were resistant to two or more of the antimicrobials. Conclusions: The high frequency of naturally occurring, antimicrobial-resistant strains of H pylori poses a national and world-wide problem for public health.


Assuntos
Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antibacterianos/farmacologia , Claritromicina/farmacologia , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Helicobacter pylori/efeitos dos fármacos , Metronidazol/farmacologia , Tetraciclina/farmacologia , Distribuição por Idade , Chile , Infecções por Helicobacter/tratamento farmacológico , Testes de Sensibilidade Microbiana , Resistência a Tetraciclina/efeitos dos fármacos
5.
Rev. méd. Chile ; 122(11): 1316-7, nov. 1994. tab
Artigo em Espanhol | LILACS | ID: lil-144033

RESUMO

During workshop, hepatologists analyzed and gave recomendations about gallbladder polyps. They arrived to the following agreements: gallbladder polyps of less than 10 mm should be followed with ultrasonography at 3, 6 and 12 months if there is no enlargement. If there is enlargement, a cholecystectomy should be performed. Polyps larger than 10 mm should be subjected to cholecystectomy


Assuntos
Humanos , Neoplasias da Vesícula Biliar/terapia , Pólipos/terapia , Ultrassonografia , Neoplasias da Vesícula Biliar/classificação , Pólipos/epidemiologia , Pólipos/patologia , Protocolos Clínicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA